Top Stories
The CSF-1R inhibitor demonstrated a 56% response rate in Phase III, alongside improvements in pain and physical function.
The companies first entered into a deal in 2024, under which AstraZeneca gained exclusive rights to Omniose's bioconjugation platform.
The Danish pharma attributed the upgrade in part to migraine drug Vyepti's continued "strong performance" in the US.
The company plans to seek FDA approval of istoglogene autogetemcel (risto-cel), formerly known as BEAM-101, by the end of the year.
Funnel Biosciences launched in February with support from investor Yijing Capital.
Conference News
Boehringer Ingelheim's survodutide showcased its safety in a cardiovascular outcomes trial (CVOT), but tolerability concerns could prove to be a thorn in its side. FirstWord is polling physicians to get their take on the readout.
Xenon is targeting a potential 2027 launch for its first-in-class focal epilepsy drug azetukalner. A FirstWord survey of 100 neurologists and epileptologists indicates that while the drug will see early uptake, its commercial trajectory may be blunted by safety data emerging from ongoing depression
Oral presentation at ACR Convergence uncovers the role of the CD40 pathway in myositis and potential therapeutic benefit of ABX1200, a novel CD71-Centyrin CD40-siRNA conjugatePHILADELPHIA, Nov. 10, 20...
Single administration of CIDEBsiRNA resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeksData shared in oral presentation at AASLD The Liver Mee...
Oral presentation includes data demonstrating armored allogeneic CD19 CAR T cells elicited a nearly 20-fold greater expansion than unarmored cells and more sustained B-cell depletion in humanized mice...
